Real-Time PCR and Statistical Analyses of acrAB and ramA Expression in Clinical Isolates of Klebsiella pneumoniae
- 1 September 2008
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 52 (9), 3430-3432
- https://doi.org/10.1128/aac.00591-08
Abstract
Clinical isolates of Klebsiella pneumoniae were tested for a correlation between tigecycline MIC and expression of ramA by using real-time PCR. At MICs of 4 and 8 μg/ml, the expression of ramA was statistically significantly different from MICs of 2 μg/ml or less, supporting the tigecycline susceptibility breakpoint of ≤2 μg/ml for K. pneumoniae .This publication has 9 references indexed in Scilit:
- MarA-mediated overexpression of the AcrAB efflux pump results in decreased susceptibility to tigecycline in Escherichia coliJournal of Antimicrobial Chemotherapy, 2007
- AdeABC multidrug efflux pump is associated with decreased susceptibility to tigecycline in Acinetobacter calcoaceticus–Acinetobacter baumannii complexJournal of Antimicrobial Chemotherapy, 2007
- RamA, a Transcriptional Regulator, and AcrAB, an RND-Type Efflux Pump, are Associated with Decreased Susceptibility to Tigecycline inEnterobacter cloacaeMicrobial Drug Resistance, 2007
- Influence of Transcriptional Activator RamA on Expression of Multidrug Efflux Pump AcrAB and Tigecycline Susceptibility in Klebsiella pneumoniaeAntimicrobial Agents and Chemotherapy, 2005
- AcrAB Efflux Pump Plays a Role in Decreased Susceptibility to Tigecycline in Morganella morganiiAntimicrobial Agents and Chemotherapy, 2005
- Efflux-Mediated Resistance to Tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1Antimicrobial Agents and Chemotherapy, 2003
- AcrAB Multidrug Efflux Pump Is Associated with Reduced Levels of Susceptibility to Tigecycline (GAR-936) in Proteus mirabilisAntimicrobial Agents and Chemotherapy, 2003
- Establishing MIC breakpoints and the interpretation of in vitro susceptibility testsJournal of Antimicrobial Chemotherapy, 2001
- In Vitro and In Vivo Antibacterial Activities of a Novel Glycylcycline, the 9- t -Butylglycylamido Derivative of Minocycline (GAR-936)Antimicrobial Agents and Chemotherapy, 1999